CathVision Aps
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CathVision Aps - overview
Established
2010
Location
Copenhagen, -, Denmark
Primary Industry
Medical Devices & Equipment
About
CathVision Aps specializes in advanced electrophysiology technology, focusing on the development of the ECGenius™ System and CARDIALYTICS™ suite to enhance cardiac signal recording and patient care in heart rhythm disorder diagnostics. Founded in 2010 in Copenhagen, Denmark, CathVision Aps is dedicated to developing high-fidelity electrophysiology systems. The company has completed 8 deals, with its most recent funding round occurring on July 18, 2023, raising USD 9. 00 mn.
The firm was founded by Rune Ørndrup, who has a history of entrepreneurship in technology and healthcare. The current CEO is Mads Matthiesen. CathVision primarily offers the ECGenius™ System, a high-fidelity, low-noise electrophysiology (EP) recording technology that enhances the quality of cardiac electrical signals crucial for diagnosing and treating heart rhythm disorders. The system includes automated, AI-based algorithms that support clinical decision-making.
Additionally, the CARDIALYTICS™ suite provides advanced AI-based analytic tools for complex atrial arrhythmia treatment, with products marketed in the United States and Europe to hospitals and electrophysiology labs, emphasizing improved patient outcomes. CathVision's revenue model is based on B2B sales to healthcare providers such as hospitals and specialized clinics. The flagship products, ECGenius™ System and CARDIALYTICS™ analytics suite, generate revenue through direct sales, initial capital expenditures for equipment acquisition, and ongoing maintenance service agreements. The recent funding round of USD 9.
00 mn is aimed at accelerating product commercialization, which is vital for sustaining revenue growth. In July 2023, CathVision raised USD 9. 00 mn in venture funding to enhance the adoption of its ECGenius™ System and support the development of its AI-powered analytic modules. The company plans to expand its sales team and continue developing its CARDIALYTICS™ suite while targeting growth in the U.
S. market.
Current Investors
Vaekstfonden, Borean Innovation, Innovation Fund Denmark
Primary Industry
Medical Devices & Equipment
Sub Industries
Monitoring Equipment, Therapeutic Devices
Website
www.cathvision.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
CathVision Aps - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | - | (276,386) | (193,680) | (537,834) | (1,096,090) | (1,537,819) | (4,017,630) | (6,798,744) | (8,755,627) | - | - | - |
| Operating Income (USD) | (18,914) | (276,491) | (196,119) | (541,789) | (1,099,392) | (1,551,900) | (4,041,534) | (6,923,731) | (8,920,578) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (32,909) | (239,721) | (251,935) | (547,706) | (1,194,001) | (1,519,331) | (3,087,698) | (4,555,623) | (6,299,910) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | - | - |
CathVision Aps - employee data
CathVision Aps - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.